No. of patients | 56 |
---|---|
No. of samples | 56 (100%) |
Median age (years) | 72 ± 10.9 |
Gender | |
Male | 33 (59%) |
Female | 23 (41%) |
Location (n = 55) | |
Right | 16 (29%) |
Left | 39 (71%) |
Grading | |
Well | 6 (11%) |
Moderate | 24 (43%) |
Poor | 26 (46%) |
Growth pattern | |
Expanding | 36 (64%) |
Infiltrating | 20 (36%) |
Budding intensity | |
Low-grade | 40 (71%) |
High-grade | 16 (29%) |
Lymph vessel infiltration | |
L0 | 37 (66%) |
L1 | 19 (34%) |
Blood vessel infiltration | |
V0 | 46 (82%) |
V1 | 10 (18%) |
MMR protein expression | |
MMR proteins expressed | 49 (87%) |
Loss of MLH1 + PMS2 | 6 (11%) |
Loss of PMS2 | 1 (2%) |
KRAS status (n = 55) | |
KRAS wild-type | 32 (58%) |
KRAS G12D | 9 (16%) |
KRAS G12V | 7 (13%) |
KRAS G12C | 1 (2%) |
KRAS G12S | 1 (2%) |
KRAS G13D | 5 (9%) |
BRAF status | |
BRAF wild-type | 54 (96%) |
BRAF V600E | 2 (4%) |
UICC Stage (n = 55) | |
I | 16 (29%) |
II | 15 (27%) |
III | 17 (31%) |
IV | 7 (13%) |